idelalisib + rituximab + chlorambucil

Idelalisib + rituximab + chlorambucil is an experimental **triple combination regimen** used for the treatment of **relapsed or refractory chronic lymphocytic leukemia (CLL)** and other indolent B-cell lymphomas. **Idelalisib** is a first-in-class, oral, small molecule inhibitor of the delta isoform of **phosphatidylinositol 3-kinase (PI3Kδ)**, primarily expressed in leukocytes, that disrupts B-cell receptor signaling pathways, promoting apoptosis and preventing tumor-microenvironment interaction[2][4][6]. **Rituximab** is a monoclonal antibody targeting the **CD20 antigen** on B lymphocytes, inducing complement-mediated, antibody-dependent cellular cytotoxicity, and direct apoptosis. **Chlorambucil** is an alkylating agent that crosslinks DNA to inhibit tumor cell proliferation. The combination of idelalisib and rituximab is FDA-approved for CLL; addition of chlorambucil is investigational and may further enhance efficacy in specific patient populations but is not standard of care[1][3]. Safety warnings include elevated risk of infections, hepatotoxicity, diarrhea/colitis, and myelosuppression[1][4][5].

Brand names

Zydelig (idelalisib)Rituxan (rituximab)Leukeran (chlorambucil)